IN8bio, Inc.
INABHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeIN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and. With a market capitalization of $11.9M, it sits in micro-cap territory. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Market Cap
$11.9M
Beta
0.22
P/E (TTM)
—
P/E (Fwd)
-1.17
EPS (TTM)
$-2.51
EPS (Fwd)
$-1.06
ROE
-103.6%
ROA
-52.8%
Cash
$21.9M
Total Debt
$2.4M
Free CF
-$7.6M
52W Change
-47.7%
Annual Financials
Cash vs Debt
Where INAB stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, INAB finished 18.82% below its 150-day moving average ($1.70) and 22.03% below its 200-day moving average ($1.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INAB overbought or oversold?
At the July 15, 2026 close, INAB's RSI(14) was 41.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $21.9M in cash comfortably exceeding the $2.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$7.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -103.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
INAB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence IN8bio, Inc.'s trajectory.